Concurrent Chemoradiotherapy for Resectable Squamous Cell Carcinoma of the Larynx
スポンサーリンク
概要
- 論文の詳細を見る
Objectives : To evaluate the efficacy and toxicity of concurrent chemoradiotherapy in patients with resectable squamous cell carcinoma (SCC) of the larynx and to demonstrate the feasibility of larynx preservation.<BR>Patients and Methods : Forty-eight eligible patients were treated with two chemotherapy regimens between March 1998 and September 2003. One of the chemotherapy regimens consisted of a combination of four drugs : cisplatin, 5-fluorouracil, methotrexate, and leucovorin (CF-MTX-LV). The other regimen consisted of two drugs : carboplatin and UFT (CBDCA-UFT). Radiotherapy was delivered 5 days a week using a single daily fraction of 1.8 to 2.0 Gray, to a total dose of 66.6 to 70.2 Gray.<BR>Results : The 5-year disease-specific survival and larynx preservation rates of cases receiving CF-MTX-LV were 85% and 50%, respectively. The 3-year disease-specific survival and larynx preservation rates of cases receiving CBDCA-UFT were 94.4% and 73.7%, respectively. The main toxicities in those treatment modalities were neutropenia, dermatitis, mucositis, infection, and nausea/vomiting.<BR>Conclusion : Concurrent chemoradiotherapy was safe and well-tolerated in the present study. In terms of larynx preservation, the present regimens appear to be useful for selective patients with resectable SCC of the larynx.
- The Japan Laryngological Associationの論文
The Japan Laryngological Association | 論文
- Innervation of the Larynx.:Localization of the Laryngeal Neurons for the Motor, Sensory and Autonomic Nervus System in the Cat
- The Sensory Nerve Fibers in the Larynx of Cats
- Two Cases of Malignant Lymphoma of the Larynx
- HUMAN PAPILLOMAVIRUS TYPE 6 AND 11 IN LARYNGEAL PAPILLOMAS
- Clinical Observations on Bilateral Recurrent Laryngeal Nerve Paralysis